64 related articles for article (PubMed ID: 25264963)
1. The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation.
Yazici KU; Percinel I
J Child Adolesc Psychopharmacol; 2014 Nov; 24(9):525-7. PubMed ID: 25264963
[No Abstract] [Full Text] [Related]
2. Glutamatergic dysfunction in skin-picking disorder: treatment of a pediatric patient with N-acetylcysteine.
Percinel I; Yazici KU
J Clin Psychopharmacol; 2014 Dec; 34(6):772-4. PubMed ID: 25203471
[No Abstract] [Full Text] [Related]
3. [Topiramate augmentation in treatment-resistant obsessive-compulsive disorder].
Vinkers DJ; van der Wee NJ
Tijdschr Psychiatr; 2008; 50(11):747-50. PubMed ID: 18991236
[TBL] [Abstract][Full Text] [Related]
4. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder.
Sevincok L; Topuz A
J Clin Psychopharmacol; 2003 Oct; 23(5):448-50. PubMed ID: 14520120
[TBL] [Abstract][Full Text] [Related]
5. The promise of N-acetylcysteine in the treatment of obsessive-compulsive disorder.
Carollo M; Carollo N; Montan G
CNS Neurosci Ther; 2024 Feb; 30(2):e14653. PubMed ID: 38385640
[No Abstract] [Full Text] [Related]
6. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder.
Jenike MA; Baer L; Buttolph L
J Clin Psychiatry; 1991 Jan; 52(1):13-4. PubMed ID: 1988411
[TBL] [Abstract][Full Text] [Related]
7. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder.
Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK
Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647
[TBL] [Abstract][Full Text] [Related]
8. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
[TBL] [Abstract][Full Text] [Related]
9. High-dose paroxetine treatment for an adolescent with obsessive-compulsive disorder comorbid with Asperger's disorder.
Sasayama D; Sugiyama N; Imai J; Hayashida A; Harada Y; Amano N
Psychiatry Clin Neurosci; 2009 Apr; 63(2):251. PubMed ID: 19335398
[No Abstract] [Full Text] [Related]
10. Augmentation of clozapine with valproic Acid for clozapine-induced obsessive-compulsive symptoms.
Zink M; Englisch S; Knopf U; Kuwilsky A; Dressing H
Pharmacopsychiatry; 2007 Sep; 40(5):202-3. PubMed ID: 17874353
[No Abstract] [Full Text] [Related]
11. Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder.
da Rocha FF; Correa H
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1550-1. PubMed ID: 17692447
[No Abstract] [Full Text] [Related]
12. Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder.
Pato MT; Pigott TA; Hill JL; Grover GN; Bernstein S; Murphy DL
Am J Psychiatry; 1991 Jan; 148(1):127-9. PubMed ID: 1984696
[TBL] [Abstract][Full Text] [Related]
13. The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder.
Rubio G; Jiménez-Arriero MA; Martínez-Gras I; Manzanares J; Palomo T
J Clin Psychopharmacol; 2006 Jun; 26(3):341-4. PubMed ID: 16702907
[No Abstract] [Full Text] [Related]
14. Glutamatergic dysfunction--newer targets for anti-obsessional drugs.
Bhattacharyya S; Chakraborty K
Recent Pat CNS Drug Discov; 2007 Jan; 2(1):47-55. PubMed ID: 18221217
[TBL] [Abstract][Full Text] [Related]
15. Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report.
Mukaddes NM; Abali O; Kaynak N
Psychiatry Clin Neurosci; 2003 Aug; 57(4):405-8. PubMed ID: 12839522
[TBL] [Abstract][Full Text] [Related]
16. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin.
Eriksson T
Int Clin Psychopharmacol; 2007 Jan; 22(1):57-61. PubMed ID: 17159461
[TBL] [Abstract][Full Text] [Related]
17. Paroxetine and obsessive-compulsive disorder.
Kaye NS; Dancu C
Am J Psychiatry; 1994 Oct; 151(10):1523. PubMed ID: 8092350
[No Abstract] [Full Text] [Related]
18. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
Freeman CP; Trimble MR; Deakin JF; Stokes TM; Ashford JJ
J Clin Psychiatry; 1994 Jul; 55(7):301-5. PubMed ID: 8071291
[TBL] [Abstract][Full Text] [Related]
19. Glutamatergic Agents in the Treatment of Compulsivity and Impulsivity in Child and Adolescent Psychiatry: a Systematic Review of the Literature.
Mechler K; Häge A; Schweinfurth N; Glennon JC; Dijkhuizen RM; Murphy D; Durston S; Williams S; K Buitelaar J; Banaschewski T; Dittmann RW; Tactics Consortium T
Z Kinder Jugendpsychiatr Psychother; 2018 May; 46(3):246-263. PubMed ID: 28922069
[TBL] [Abstract][Full Text] [Related]
20. N-Acetyl Cysteine and Vitamin D Supplementation in Treatment Resistant Obsessive-compulsive Disorder Patients: A General Review.
di Michele F; Siracusano A; Talamo A; Niolu C
Curr Pharm Des; 2018; 24(17):1832-1838. PubMed ID: 29663874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
